To report 3-year outcomes of a prospective, multi-center, randomized, blinded control trial after treatment with convective radiofrequency (RF) water vapor thermal therapy for moderate to severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).
Fifteen centers enrolled and randomized 197 men ≥50 years old with International Prostate Symptom Score (IPSS) ≥13, maximum flow rate (Qmax) ≤15 ml/s and prostate volume 30 to 80 cc to thermal therapy with Rezūm® System or control (2:1). Rigid cystoscopy with simulated active treatment sound effects served as the control procedure. Convective RF thermal energy was delivered into obstructive prostate tissue including the median lobe as needed. After randomized comparison at 3 months, thermal therapy subjects were followed annually for 3 years.
Convective RF thermal therapy yielded IPSS improvements 160% when compared to control subjects at 3 months (p<0.0001). Maximal symptom relief of at least 50% improvements in IPSS, quality of life, Qmax, and BPH Impact Index remained durable throughout 3 years (p<0.0001). Subjects with a treated median lobe had similar responses. No late related adverse events occurred and no de novo erectile dysfunction was reported. The surgical retreatment rate was 4.4% over 3 years.
The minimally invasive convective RF thermal therapy is an office or ambulatory outpatient procedure with minimal transient perioperative side effects. It provides early effective and durable relief of BPH symptoms with preservation of sexual function in subjects followed to 3 years and is applicable to treatment of the median lobe and hyperplastic central zone tissue.
Urology. 2017 Nov 06 [Epub ahead of print]
Kevin T McVary, Claus G Roehrborn
Division of Urology, Southern Illinois University School of Medicine, Springfield, IL. Electronic address: ., Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.